Orange Book product · Brand (NDA)

BRILINTA

TICAGRELOR

Brand (NDA)NDA 022433TE ABRX ASTRAZENECA

Sep 03, 2015

Approved

Brand (NDA)

Application

TE code

Listed patents

Approval
FDA approval date of this drug product.
Sep 03, 2015
10 yr 11 mo ago
Today
Patent 8425934 expires
Listed drug product patent expiration.
Apr 17, 2030
in 3 yr 11 mo
Patent 8425934*PED expires
Listed listed patent expiration.
Oct 17, 2030
in 4 yr 5 mo
Patent 10300065 expires
Listed method-of-use patent (U-2541) expiration.
Jan 27, 2036
in 9 yr 9 mo
Patent 10300065 expires
Listed method-of-use patent (U-2542) expiration.
Jan 27, 2036
in 9 yr 9 mo
Patent 10300065*PED expires
Listed listed patent expiration.
Jul 27, 2036
in 10 yr 3 mo

Active ingredient

TICAGRELOR

Strength

60MG

Dosage form

TABLET

Route

ORAL

TE code

Application

NDA 022433

Product number

002

Marketing status

Reference listed drug (RLD)

Yes

Reference standard (RS)

Active-ingredient family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
Patent	Expires	In	Type
8425934	Apr 17, 2030	in 3 yr 11 mo	Product
8425934*PED	Oct 17, 2030	in 4 yr 5 mo
10300065	Jan 27, 2036	in 9 yr 9 mo	U-2541
10300065	Jan 27, 2036	in 9 yr 9 mo	U-2542
10300065*PED	Jul 27, 2036	in 10 yr 3 mo